---
title: "Detectability floor limits treatment-response labels in rheumatology transcriptomics"
id: "medrxiv-0-a-detectability-floor-for-treatment-response-labels-in-rheumatology"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-a-detectability-floor-for-treatment-response-labels-in-rheumatology"
content_type: "clinical_feed_article"
specialty: "Rheumatology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1?rss=1"
published_at: "2026-10-06T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Detectability floor limits treatment-response labels in rheumatology transcriptomics
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-a-detectability-floor-for-treatment-response-labels-in-rheumatology
- **Specialty:** [Rheumatology](https://medichelpline.com/clinical-feed/rheumatology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1?rss=1)
- **Published At:** 2026-10-06T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Objective: The authors tested whether commonly used **treatment-exposure** and **response-prediction** transcriptomic labels in rheumatic diseases are below a study's **detectability floor**, while matched **disease-state** labels remain detectable. - Datasets: Eight public datasets were audited, including paired juvenile dermatomyositis (n=10), rheumatoid arthritis before/after methotrexate (n=28 pairs), lupus nephritis (n=10), controlled exposure experiments, and a single-cell dose series. - Methods: Five published signatures and one benchmark trajectory were evaluated in each analysable cohort. Audits used effect sizes (dz) compared to each design's minimum detectable effect (the design floor). A pre-registered taxonomy and analysis scripts were deposited to Zenodo; dataset accessions are listed in the paper's tables and supplements. - Main findings — disease-state labels: Disease-state labels were detectable. Example: an **interferon signature** declined in 10/10 juvenile dermatomyositis patients (p = 0.002), explaining 59.5% of score variance. - Main findings — exposure and response labels: No clinical cohort showed an exposure label that cleared its design floor. One methotrexate-matched prior was nominally significant in juvenile dermatomyositis but did not clear its floor (dz = -0.80; CI spanned the floor). Exposure became detectable only when prior context and intensity were both favorable (e.g., multi-day target tissue dz = 1.24, q = 0.018; well-level pseudobulk dz = +3.70 with floor 1.80). - Audit verdicts: Audited response labels failed in 14 of 15 cohorts (93%; descriptive binomial 95% CI 68–100): eleven cohorts were below their floors and three were sign-reversed. The largest training cohort pooled to near zero effect (dz = +0.07; I2 = 69%). - Relationship to reported performance: Effect size ordering matched reported AUCs monotonically. - Conclusion: Under conventional treatment intensities, many exposure and response-prediction transcriptomic labels are either undetectable (below the design floor) or replicate with the wrong sign, while **disease-state** signatures are detectable. Some negative literature may reflect these design limitations rather than absence of biology. - Other notes: This is a preprint not peer reviewed. Data and code are publicly referenced; some Zenodo materials have restricted access for review. Authors declared no competing interests.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=LDkxlELasSmWuS_2YVPHOFG49tQtrAszxpgxtJrPC9g-1791316726.2307575-1.2.1.1-hxmuRmnmrBfAbDPg9JIYOeDLcT9BNfvOO3d8C8JQ6gPEsdzGk5IvZwzi_CoMQP37) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # A detectability floor for treatment-response labels in rheumatology transcriptomics [ View ORCID Profile](http://orcid.org/0009-0006-6148-6018)Haitao Yang, [ View ORCID Profile](http://orcid.org/0009-0007-7067-5416)Yan Huang, [ View ORCID Profile](http://orcid.org/0009-0005-9737-7086)Jianghua Xu, [ View ORCID Profile](http://orcid.org/0009-0004-9602-7634)Suo Zhang, [ View ORCID Profile](http://orcid.org/0000-0001-7529-6377)Rui Liao doi: https://doi.org/10.64898/2026.10.04.26364671 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Haitao Yang 1 People's Hospital of Longhua, Shenzhen, Guangdong 518109, P.R. China; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Haitao%2BYang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yang%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHaitao%2BYang%2B) * [ORCID record for Haitao Yang](http://orcid.org/0009-0006-6148-6018 "Open in new tab") * For correspondence: haitaoyang916@163.com Yan Huang 2 Department of Internal Medicine, Kuichong People's Hospital, Shenzhen, Guangdong 518119, P.R. China; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yan%2BHuang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Huang%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYan%2BHuang%2B) * [ORCID record for Yan Huang](http://orcid.org/0009-0007-7067-5416 "Open in new tab") Jianghua Xu 3 Department of Medical Service for Special Forces, General Hospital of Southern Theater Command, Guangzhou, Guangdong 510010, P.R. China; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jianghua%2BXu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Xu%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJianghua%2BXu%2B) * [ORCID record for Jianghua Xu](http://orcid.org/0009-0005-9737-7086 "Open in new tab") Suo Zhang 4 Department of Rheumatology and Immunology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518032, P.R. China; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Suo%2BZhang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zhang%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASuo%2BZhang%2B) * [ORCID record for Suo Zhang](http://orcid.org/0009-0004-9602-7634 "Open in new tab") Rui Liao 5 Department of Rheumatology and Immunology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rui%2BLiao%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Liao%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARui%2BLiao%2B) * [ORCID record for Rui Liao](http://orcid.org/0000-0001-7529-6377 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1315130/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1315130/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1315130/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1315130/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1315130/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1315130/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objectives. Before-and-after transcriptomics in rheumatic disease often yields no reproducible treatment signal, though disease-state stratification is robust. We asked whether exposure and response-prediction labels fall below the detection floor of the designs defining them, while matched disease-state labels do not. Methods. Eight public datasets were analysed (paired juvenile dermatomyositis n = 10; RA before/after methotrexate, n = 28 pairs; lupus nephritis n = 10; controlled exposures; a single-cell dose series). Response labels in current use (one benchmark trajectory, five published signatures) were audited in every analysable source cohort, using effect sizes (dz) against each design's exact minimum detectable effect. Results. Disease-state labels were detectable: the interferon signature declined in 10/10 juvenile dermatomyositis patients (p = 0.002; 59.5% of score variance). No exposure label cleared its design floor in any clinical cohort; a drug-matched methotrexate prior was nominally significant in juvenile dermatomyositis yet did not clear its floor (dz = -0.80; CI spanning it). Exposure became detectable only where prior-context and intensity were jointly favourable (multi-day target tissue dz = 1.24, q = 0.018; well-level pseudobulk dz = +3.70, floor 1.80). Audited response labels failed in 14 of 15 cohorts (93%; descriptive binomial 95% CI 68-100): eleven below their floors, three sign-reversed; the largest training cohort pooled to zero (dz = +0.07; I2 = 69%). Effect size ordered reported AUCs monotonically. Conclusion. Under conventional treatment intensities, exposure and response-prediction labels are either undetectable below the design floor or detected with a sign that does not replicate; disease-state labels are detectable. Part of the negative literature reflects a design floor. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All datasets analysed are publicly available; accessions and designs are listed in Table 1 and annotation provenance for the extended audit in Supplementary Table S1. Analysis scripts, adjudication ledgers, per-sample mapping tables and the pre-registered verdict taxonomy are deposited at Zenodo (doi:10.5281/zenodo.23123981), with restricted access and a private review link for reviewers. The pre-registration predates every verdict reported. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.05.31.26354544v2 "Context-dependent molecular responses to heterogeneous metabolic disease traits") Posted October 06, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/06/2026.10.04.26364671.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.10.04.26364671v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/06/2026.10.04.26364671.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) A detectability floor for treatment-response labels in rheumatology transcriptomics Haitao Yang, Yan Huang, Jianghua Xu, Suo Zhang, Rui Liao medRxiv 2026.10.04.26364671; doi: https://doi.org/10.64898/2026.10.04.26364671 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.04.26364671v1%26text%3DA%2520detectability%2520floor%2520for%2520treatment-response%2520labels%2520in%2520rheumatology%2520transcriptomics "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.04.26364671v1%26t%3DA%2520detectability%2520floor%2520for%2520treatment-response%2520labels%2520in%2520rheumatology%2520transcriptomics "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.04.26364671v1%26title%3DA%2520detectability%2520floor%2520for%2520treatment-response%2520labels%2520in%2520rheumatology%2520transcriptomics%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.04.26364671v1%26title%3DA%2520detectability%2520floor%2520for%2520treatment-response%2520labels%2520in%2520rheumatology%2520transcriptomics "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.10.04.26364671) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.10.04.26364671v1&count=horizontal&via=&text=A%20detectability%20floor%20for%20treatment-response%20labels%20in%20rheumatology%20transcriptomics&counturl=www.medrxiv.org/content/10.64898/2026.10.04.26364671v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (626) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (914) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (340) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4886) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (486) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (421) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (659) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1645) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16067) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (34) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1218) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7129) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (737) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1073) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5127) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1447) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1793) * [Hematology](https://www.medrxiv.org/collection/hematology) (591) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1355) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16360) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1185) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (678) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (729) * [Neurology](https://www.medrxiv.org/collection/neurology) (7388) * [Nursing](https://www.medrxiv.org/collection/nursing) (371) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1102) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1263) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1010) * [Oncology](https://www.medrxiv.org/collection/oncology) (3660) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1066) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (399) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (460) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (483) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (142) * [Pathology](https://www.medrxiv.org/collection/pathology) (711) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1823) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (741) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (777) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5988) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9836) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2467) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1479) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1257) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (651) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (786) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (588) * [Surgery](https://www.medrxiv.org/collection/surgery) (786) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (310) * [Urology](https://www.medrxiv.org/collection/urology) (298) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which participating organizations post peer reviews of manuscripts they are evaluating _There is no TRiP material for this paper._ Community Reviews medRxiv aims to
## Related Clinical Research

- [ZnT8 autoantibodies are common in rheumatoid arthritis and identify synovial lining fibroblasts as](https://medichelpline.com/clinical-feed/medrxiv-12-diabetes-related-antibody-signature-highlights-znt8-as-a-novel-antigenic-target.md)
- [COVID-19 Burden in Adults with Systemic Autoimmune Rheumatic Diseases in Quebec, 2020–2023](https://medichelpline.com/clinical-feed/medrxiv-15-comparative-burden-of-covid-19-in-adults-with-rheumatic-diseases-and.md)
- [Moderate-to-severe chronic spontaneous urticaria linked to higher risk of rheumatoid arthritis and](https://medichelpline.com/clinical-feed/plos-one-9-moderate-to-severe-chronic-spontaneous-urticaria-is-associated-with-increased.md)
- [Serum Metrnl in Neuromyelitis Optica Spectrum Disorder: Article content unavailable in source](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-characteristics-of-serum-metrnl-levels-in-patients-with-neuromyelitis-optica.md)
- [Current immunosuppressive treatment and self-reported lifetime stroke history in US adults](https://medichelpline.com/clinical-feed/plos-one-4-current-immunosuppressive-treatment-and-self-reported-lifetime-stroke-history.md)

## Navigation
- [← Back to Rheumatology Feed](https://medichelpline.com/clinical-feed/rheumatology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.